AN2 Therapeutics, Inc.
ANTX
$4.27
-$0.45-9.53%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -8.71M | -9.35M | -6.46M | -10.65M | -7.52M |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 1.28M | 590.00K | 1.70M | 1.60M | 1.21M |
| Change in Net Operating Assets | 2.19M | 2.39M | -2.84M | -1.58M | 1.04M |
| Cash from Operations | -5.24M | -6.38M | -7.60M | -10.62M | -5.27M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 7.17M | 6.11M | 5.83M | 9.19M | -6.88M |
| Cash from Investing | 7.17M | 6.11M | 5.83M | 9.19M | -6.88M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 0.00 | 48.00K | 0.00 | 65.00K | 0.00 |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 0.00 | 48.00K | 0.00 | 65.00K | 0.00 |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 1.94M | -217.00K | -1.77M | -1.37M | -12.15M |